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PLATELET-DERIVED GROWTH FACTOR ENABLES DIRECT DERIVATION OF 
OLIGODENDROCYTE PROGENITORS FROM CNS STEM CELLS 
Rajesh C. Rao and Ronald D. McKay. Laboratory of Molecular Biology, National Institute of 
Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD. (Sponsored by Diane 
S. Krause, Department of Laboratory Medicine, Yale University School of Medicine).  
 
Oligodendrocytes derived in the laboratory from stem cells have been proposed as a treatment for 
acute and chronic injury to the central nervous system (CNS).  Platelet-derived growth factor-receptor 
alpha (PDGFRα) signaling is known to play an important role for regulation of oligodendrocyte 
progenitor cell numbers both during development and adulthood. Here, we analyze the effect of 
PDGFRα signaling on CNS stem cells derived from embryonic day 13.5 murine cortex and cultured 
in monolayer. Fetal and adult CNS stem cells express PDGFRα, and PDGF-AA treatment increases 
viability and proliferation of these cells. In the absence of insulin, this effect of PDGF-AA is very 
clear. Consistent with this result, PDGF-AA strongly stimulates glycolytic rate. PDGF-AA treatment 
rapidly induces morphological changes in the cells although the cells maintain expression of a wide 
range of precursor markers. We show that a brief exposure to PDGF-AA rapidly and efficiently 
induces oligodendrocytes from CNS stem cells.  Our data suggest that phosphoinositide kinase-3 
(PI3K)/Akt, mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-
related kinase (MEK/Erk), mammalian target of rapamycin (mTOR) regulate survival, proliferation, 
glycolytic rate, and oligodendrogliogenesis induced by PDGF-AA. By treating with PDGF-AA, 
progenitor cells directly from embryonic cortex can be expanded and differentiated into 
oligodendrocytes with high efficiency. Our results show that PDGF-AA promotes oligodendrocyte 
progenitor generation from CNS stem cells and supports their survival and proliferation. The 
derivation of oligodendrocytes demonstrated here may support the safe and effective use of stem cells 
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Oligodendrocyte progenitors are dividing, lineage-restricted precursors that exist in both 
the developing and adult central nervous system (CNS) and differentiate into 
oligodendrocytes, the cell type responsible for myelination of CNS axons (1).   In vivo, 
oligodendrocyte progenitors arise in distinct temporal waves starting from embryonic day 
12.5 (E12.5) in the ventral forebrain, which then migrate laterally and dorsally, arriving 
in the cortex by E16 (2).  Historically, the isolation of oligodendrocyte progenitors has 
involved extensive, multistep purification procedures from postnatal tissues of the 
forebrain and optic nerve (3, 4).  The transplantation of this cell population has been 
proposed as a therapeutic approach to treat demyelinating diseases such as multiple 
sclerosis, and spinal cord injury (5-7). 
 
Multipotent stem cells that are the precursors to oligodendroglial, astroglial, and neuronal 
progenitors can be readily derived from the fetal and adult brain of many mammals and 
expanded to large numbers (8, 9).  Neural stem cells can also be efficiently generated 
from embryonic stem (ES) cells (10, 11).  Stem cells have been proposed as a source of 
oligodendrocytes to treat demyelinating disease and transplantation of human ES cell 
derived oligodendrocyte progenitors in spinal cord injury is imminent (12-14).  Cytokine 
signaling regulates the production of differentiated cell types from stem cells in vitro (15).  
Transplantation shows that the in vitro system generates functional oligodendrocytes but 





Platelet-derived growth factor (PDGF) was initially identified because of its role in the 
proliferation of glial cells and its oncogenic function in sarcoma virus (16-18).  The 
subsequent identification of the PDGF receptor has had an important role in defining 
membrane events that trigger proliferation (19-21).  PDGF and its receptors are expressed 
in several different cell types in the developing and adult CNS (22).   PDGF ligands A, B, 
C, and D occur as homodimers and as a heterodimer (AB) and bind two tyrosine kinase 
cell surface receptors, PDGFRα and PDGFRβ.  Most of the ligands (AA, AB, BB, CC) 
bind PDGFRα while a subset (BB, DD) bind PDGFRβ.  Ligand binding to PDGF 
receptor induces receptor dimerization, followed by activation of tyrosine kinase domains, 
and autophosphorylation of tyrosine residues on the cytoplasmic domain of the receptor 
(22). Docking proteins and signal adaptors interact with the phosphorylated tyrosine 
residues to initiate downstream signaling cascades important for cell metabolism, growth 
and survival, including the phosphoinositide kinase-3/Akt/ mammalian target of 
rapamycin (PI3K/Akt/mTOR) and mitogen-activated protein/extracellular signal-
regulated kinase kinase/extracellular signal-related kinase (MEK/Erk) pathways (23-25).   
 
In the CNS, PDGFRα is expressed by neuroepithelial cells as early as E8.5, retinal 
astrocytes, oligodendrocyte progenitors, developing and adult neurons, and adult neural 
stem cells in the subventricular zone (SVZ) (26-30).  PDGFRα-null mice are not viable; 
lethality is seen between embryonic day 9.5 and 16 (E9.5-16). These embryos show 
multiple CNS defects, including failure of neural tube closure and neural crest 
abnormalities (31, 32). Several defects in oligodendrocyte development related to 
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impaired PDGFRα signaling are observed. PDGFRα haploinsufficient animals, which 
survive long enough for oligodendrogliogenesis to occur, display precocious 
differentiation of oligodendrocytes progenitors in vivo and in vitro (32). The PI3K/Akt 
pathway is a particularly important downstream effector of this receptor as knockin mice 
harboring mutations in PDGFRα that selectively eliminate its capacity to activate PI3K 
die perinatally and display several defects, including impaired migration of 
oligodendrocytes progenitors and generalized hypomyelination (32, 33).  Conditional 
inactivation of PDGFRα in adult SVZ neural stem cells results in a severe reduction in 
stem cell-derived oligodendrocytes (29).  
 
PDGF-A plays a specific role in the developing CNS. PDGF-A knockout mice, when 
compared to wild-type or PDGF-B null mice, have reduced numbers of oligodendrocytes, 
display severe hypomyelination and a dysmyelinating phenotype (tremor), which argues 
for an essential role of the ligand in oligodendrocyte development (34). In vitro, PDGF-
AA is generated by astrocytes and is a more potent mitogen for oligodendrocyte 
progenitors than are other isoforms (35-38).  In the adult brain, infusion of exogenous 
PDGF-AA shifts cell production of SVZ neural stem cells from neurogenesis to 
oligodendrogliogenesis in vivo (29).  In the mouse embryo, PDGF-A and PDGFRα are 
expressed in adjacent layers; PDGF-A is the predominant isoform expressed in the 
developing CNS (38, 39). 
 
Apart from these developmental roles, PDGF signaling has been implicated in CNS 
tumorigenesis. Autocrine PDGF signaling—most commonly overexpression of the ligand 
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and/or receptor—is found in essentially 100% of human gliomas (40).  Indeed, gene 
transfer of PDGF-AA, has been shown to promote tumor-like formation in vivo (41, 42).  
Continuous, in vivo ventricular infusion of PDGF-AA into the adult brain induces the 
formation of large, SVZ stem cell-derived hyperplasias with some features of glioma (29). 
 
In this manuscript, we report the effects of PDGF-AA on neural stem cells derived from 
the fetal cerebral cortex. Continuous treatment of CNS stem cells with PDGF-AA 
maintains expression of neural precursor markers and increases viability, proliferation, 
nestin+ cell number and glycolytic rate. The increased cell number and glycolytic rate 
observed with PDGF-AA treatment is regulated by PI3K/Akt, MEK/Erk, and mTOR 
pathways. Brief exposure to PDGF-AA rapidly induces oligodendrogliogenesis from 
CNS stem cells through MEK/Erk and PI3K/Akt pathways. Using PDGF-AA, we 
describe a one-step method to derive large numbers oligodendrocyte progenitors directly 
from embryonic cortex and CNS stem cells. These findings demonstrate that PDGF-AA 
regulates CNS stem and progenitor cell number, metabolism, and fate through particular 
intracellular signaling pathways. The efficacy and safety of the oligodendrocyte 
progenitor populations derived here can now be simply assessed. 
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Statement of Purpose, Specific Hypothesis, and Specific Aims 
 
Despite the imminent use of stem cell-derived oligodendrocytes in clinical therapy of 
spinal cord injury, there is no study that explicitly defines the transition from stem cell to 
oligodendrocyte progenitor (43, 44).  In this study, our purpose was to define this 
transition by using multipotent neural stem cells derived from the fetal cortex, which 
clonally generate oligodendrocytes, neurons, and astrocytes. Given that platelet derived 
growth factor-AA (PDGF-AA) plays an essential role in oligodendrocyte development, 
we hypothesized that the cytokine would induce oligodendrogliogenesis from CNS stem 
cells (45). Our specific aims were to generate a rapid, serum-free method to generate 
oligodendrocytes from CNS stem cells and to determine which cell signaling pathways 






Materials and Methods 
 
Cell culture. Fetal cortices were dissected free of meninges from E13.5 CD-1 mouse 
embryos (Charles River, Wilmington, MA) in Hank’s buffered saline solution (HBSS; 
Mediatech, Herndon, VA). Cortices were dissociated by brief mechanical trituration and 
resuspended in serum free medium containing Dulbecco’s modified Eagle medium 
(DMEM/F12, Mediatech) with N2 supplement (expansion medium) and fibroblast 
growth factor-2 (FGF2, 20 ng/ml, added daily, R&D Systems, Minneapolis, MN). N2 
supplement contains 25 μg/ml insulin, 100 μg/ml human apotransferrin, 20 nM 
progesterone, 100 μM putrescine, 30 nM sodium selenite (all from Sigma-Aldrich, St. 
Louis, MO) (46). CNS stem cells from passaged at ~60% confluence by briefly 
incubating in HBSS and gently scraped with a cell scraper. CNS stem cells from passage 
1 were plated at 5,000-25,000 cells/cm2. FGF2 was included throughout our experiments 
unless otherwise stated. To derive, propagate and expand oligodendrocyte progenitors 
from E13.5 cortical cells or CNS stem cells, cells were cultured in PDGF-AA (30 ng/ml, 
added daily) without FGF2 (20 ng/ml, R&D Systems) in expansion media. To rapidly 
induce oligodendrogliogenesis from CNS stem cells, passage 1 stem cells were re-plated 
at 25,000 cells/cm2 in PDGF-AA containing medium for 12 hours, and cultured in serum-
free differentiation media consisting of Neurobasal media with B-27 supplement 
(Invitrogen, Carlsbad, CA) for a differentiation period of 4-5 days. To induce 
differentiation of oligodendrocyte progenitors derived from CNS stem cells or primary 
E13.5 embryonic cortical cells, PDGF-AA was withdrawn and expansion media was 




Immunocytochemistry. Cultured CNS cells were fixed with 4% paraformaldehyde and 
processed as described (47, 48). Cells were stained with primary antibodies against the 
following proteins: A2B5 (mouse monoclonal, 1:500, Chemicon, Temecula, CA), NG2 
(rabbit polyclonal, 1:100, Chemicon), O4 (mouse monoclonal, 1:50, Chemicon), BrdU 
(rat monoclonal, 1:400, Accurate, Westbury, NY), cleaved caspase-3 (rabbit polyclonal, 
1:200, Cell Signaling, Danvers, MA) , nestin (rabbit serum 130, 1:100, McKay Lab), 
Sox2 (goat polyclonal, 1:50, R&D Systems), PDGFRα (rabbit polyclonal, 1:500, Santa 
Cruz Biotech, Santa Cruz, CA), Olig2 (rabbit polyclonal, 1:5000, kind gift of H. 
Takebayashi). Appropriate secondary antibodies (Alexa Fluor 488 and 568, 1:200, 
Molecular Probes, Invitrogen) were applied and incubated for 1 hour at room temperature. 
Nuclei were stained with DAPI (0.25 µg/ml, Sigma, St. Louis, MO). Images were 
captured, using fluorescent filters, with a Zeiss Axioplan microscope and Zeiss Axiocam 
HR camera (Carl Zeiss Inc, Thornwood, NY). 
 
Measurement of glycolytic rate. CNS stem cells were plated at 6.25 x 104 cells/cm2 and 
cultured for 24 or 48 hours, and treated as indicated in the Figure legends. Cells were 
then incubated in expansion media supplemented with 10 mM glucose and 20 μCi/ml [5-
3H]glucose (Perkin Elmer, Waltham, MA) at 37oC . After 1 hour, an equal volume of 0.2 
N HCl was added to stop the reaction. 3H2O was separated from unmetabolized [5-
3H]glucose by evaporative diffusion of 3H2O in a sealed equilibration chamber. Samples 





Flow cytometry. Cells were plated at 3.12 x 104 cells/cm2 and cultured for 3 days, and 
treated as indicated in the Figure legends (growth factors added daily, media was not 
changed so that viable and nonviable cells could be analyzed). Adherent cells were 
passaged into suspension and combined with floating viable and nonviable cells and 
analyzed for viability based on propidium iodide exclusion. Flow cytometry and data 
analysis were performed by Jeanette Beers using a FACScaliber system and CELLQuest-
Pro software (BD Biosciences, San Jose, CA). 
 
Western blotting. Total cell lysates were prepared in lysis buffer (1% Triton X-100, 10% 
glycerol, 50 mM Tris, pH 7.4, 150 mM NaCl, 2 mM EDTA, 2 mM MgCl2, 1 mM DTT, 1 
mM PMSF, and phosphatase inhibitors) and were normalized for protein concentration. 
Protein was loaded on 4-12% polyacrylamide gels and transferred to nitrocellulose 
membranes (both Invitrogen, Carlsbad, CA). Primary antibodies include PDGFRα, 
PDGFβ (Santa Cruz Biotech, Santa Cruz, CA), phospho-tyrosine742-PDGFRα (Abcam, 
Cambridge, MA), phospho-serine-473-Akt, Akt, phospho-threonine-202/tyrosine-204-
Erk1/2 (Cell Signaling, Danvers, MA), and tubulin (Sigma, St. Louis MO). Blots were 
probed with HRP-conjugated secondary antibodies (1:10,000, Jackson Immunoresearch, 
West Grove, PA) followed by chemiluminescent reagent (1:2, Pierce, Rockford, IL). 
 
Pharmacologic treatments. Unless otherwise stated, we used the following 
concentrations: LY294002 (10 μM), PD98059 (50 μM), rapamycin (1 μM) (Calbiochem, 
San Diego, CA). For the effects of kinase inhibitors on activation of signaling pathways 
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following PDGF-AA treatment, cells were pre-incubated for 1 h with inhibitor prior to 
PDGF-AA administration. Control cultures were treated with DMSO vehicle. 
 
Statistical Analysis. In all experiments, mean ± s.d. or s.e.m is presented as stated. 
Asterisks identify experimental groups significantly different from control groups by the 







FGF2-responsive CNS stem cells express PDGFRα  
Murine E13.5 cortical cells were treated with fibroblast growth factor-2 (FGF2) in order 
to select for and expand CNS stem cells (15). As CNS stem cells in primary culture 
proliferated with continued FGF2 administration, increased amounts of PDGFRα, but not 
a related receptor, PDGFRβ, were detected by western blotting (Fig. 1A). 
Immunocytochemical analysis using an antibody against PDGFRα confirmed that the 
receptor is expressed by virtually all FGF2-expanded CNS stem cells (Fig 1B).  
 
PDGF-AA stimulation activates Akt, Erk, and mTOR in a sustained manner and 
maintains expression of neural precursor markers  
 
We next examined signaling induced by PDGF-AA. We found, by western blotting, that 
PDGF-AA stimulated phosphorylation of PDGFRα, with maximal activation at 5 min 
(Fig 1C).  
 
Receptor tyrosine kinases, such as insulin, FGF and PDGF receptors, are known to 
activate several downstream second messenger signaling pathways. In CNS stem cells, 
PDGF stimulation rapidly activated PI3K/Akt and Ras/MEK/Erk pathways with 
sustained kinetics: maximal activation occurred at 5 min yet phospho-Akt and Erk levels 
remained above baseline even 12h and 24h after addition of the ligand (Fig 1C). While 
we did not observe rapid activation, elevated phospho-mTOR was observed at 24h 
11 
 
following PDGF treatment (Fig. 2A). These data demonstrate that PDGF-AA activates 
key downstream survival, proliferation, and growth pathways in CNS stem cells in a 
sustained fashion over FGF2 treatment alone. 
 
Interestingly, co-stimulation with FGF2 and PDGF-AA or switching from FGF2 to 
PDGF-AA induced a rapid morphological change in CNS stem cells—in 12h, cells 
became phase-bright and bipolar. Nevertheless, PDGF-treated cells continued to divide 
and maintained expression of several neural progenitor markers shared by FGF2-






Figure 1. PDGF-AA treatment activates PI3K/Akt and MEK/Erk pathways but maintains 
expression of precursor markers in embryonic PDGFRα+ CNS stem cells. (A) Western blot (WB) 
analysis of PDGFRs α and β in E13.5 lateral cortex, and after 3d and 5d treatment with FGF2. (B) 
FGF2-treated CNS stem cells express PDGFRα (PDGFRα, green). Scale bar = 10 μm. (C) PDGF-AA 
causes phosphorylation of PDGFRα and rapid and sustained activation of MEK/Erk and PI3K/Akt 
pathways. (D,E,F,G) Passage 1 CNS stem cells with treated with FGF2 alone, FGF2 + PDGF-AA, or 
switched from FGF2 to PDGF-AA alone for 3d. PDGF-AA treated cells maintained expression of 
several precursor markers, including (D) nestin (green), Sox2 (red); (E) A2B5 (red), PDGFRα 
(green); (F) NG2 (green); (G) Olig2 (red). All nuclei (B, D-G) were stained with DAPI (blue). Scale 
bar = 20 μm.  
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PDGF-AA increases nestin+ cell number, viability, and proliferation  
 
The activation of Akt, Erk, and mTOR pathways in CNS stem cells following PDGF 
stimulation prompted us to examine whether progenitor cell number, proliferation, and 
viability may be enhanced. To this end, we cultured CNS stem cells (passage 1) and 
primary E13.5 cortical cells at low density (5,000 cells/cm2), and assessed cell number 4d 
later. PDGF-AA treatment increased nestin-positive cell number in FGF2-expanded CNS 
stem cells and in primary E13.5 cortical cells by two to three-fold (316 ± 18.6% and 233 
± 37.9% of FGF2-treated controls, respectively; p < 0.02; Fig 2A, 3B). The increases in 
cell number correlated with increased Erk1/2, Akt, and mTOR phosphorylation (at 24 h) 
in PDGF-treated cultures versus control cultures in FGF2 alone (Fig 2A)  The PDGF-AA 
mediated increase in cell number was completely suppressed by pretreatment with the 
PI3K, MEK, and mTOR inhibitors, LY294002 (10 μM), PD98059 (50μM), rapamycin 
(1μM), respectively (62.5 ± 21.1%, 65.9 ± 13.0%, 127 ± 37.2%, respectively, vs. 316 ± 
18.6% FGF2+PDGF-AA, p < 0.03, Fig 2A). Western blotting confirmed inhibition of 
these three pathways (Fig 2A). These data show that the Akt, Erk1/2, and mTOR 
pathways are required for this effect. 
 
To assess whether the PDGF-AA induced increase in cell number was due to changes in 
proliferation, cells were pulsed with BrdU (10μg/ml) for increasing periods of time, and 
the proportion of cells undergoing S-phase during each pulse was analyzed by 
immunocytochemistry. At each pulse length, a consistent increase in BrdU incorporation 
was observed among PDGF-AA treated cells compared to control cells (e.g. for a 12h 
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pulse, 71.1 ±  4.15% for FGF2 vs. 86.2 ± 1.51% for FGF2 + PDGF-AA;  p < 0.015 at all 
pulse lengths; n = 3 for each pulse; Fig 2B). However, we found the slopes during the 
linear and plateau phases of the BrdU incorporation curve to be similar between both 
groups indicating that PDGF-AA does not change cell cycle length (data not shown). A 
modest but significant increase in cell viability was observed by PDGF-AA treatment, as 
measured by propidium iodide exclusion (61.3 ± 4.62% in controls to 69.5 ± 0.955%, *p 
< 0.05; n = 3; Fig 2F). These data demonstrate that PDGF treatment, through relatively 
modest changes in replication and survival rates, results in significant increases in 





Figure 2. PDGF-AA increases nestin+ cell number, viability, and proliferation; and activates 
mTOR PI3K/Akt, MEK/Erk pathways. (A) CNS stem cells were plated at low density (5,000 
cells/cm2) and grown for 4d ± FGF2, PDGF-AA, inhibitors of PI3K (LY, LY294002, 10μM), MEK 
(PD, PD98059, 50μM) and mTOR (RAPA, rapamycin, 1μM). Cell number (mean ± s.d., n = 4, *p < 
0.03) is expressed as percent of control (FGF2). WB analyses confirm inhibition of mTOR PI3K/Akt, 
MEK/Erk pathways. (B) CNS stem cells treated with FGF2 alone vs. FGF2 and PDGF-AA were 
pulsed with 10μM BrdU for increasing time periods, fixed, and labeled with anti-BrdU antibody 
(mean ± s.d., n = 3, *p < 0.015). To compare S-phase entry of control cells with cells switched from 
FGF2 to PDGF-AA, cells were pulsed for 24h, and labeled with anti-BrdU antibody (mean ± s.d., n = 
3 per time point, n.s. = non-significant). (C) CNS stem cells were grown for 3 d ± FGF2, PDGF-AA, 





PDGF-AA maintains cell number, viability, and proliferation in the absence of 
FGF2 and insulin  
 
CNS stem cells are cultured in vitro with high concentrations of insulin (25 μg/ml), a 
growth factor known to activate several downstream intracellular signaling cascades, 
including PI3K/Akt, MEK/Erk, and mTOR pathways and to promote cell survival and 
proliferation (49). To assess potential effects of PDGF on CNS stem cells that insulin 
may mask, we cultured cells in the absence of insulin. In our low density plating assay, in 
the presence of FGF2, 4 d insulin withdrawal resulted in a significantly diminished cell 
number (9.88 ± 2.30% of control, p < 0.0002, Fig 3A). However, PDGF-AA treatment 
rescued cell number (FGF2+PDGF: 93 ± 14.85%; PDGF only: 46.7 ± 7.31%; Fig 3A).  
 
Interestingly, cultures in PDGF-AA alone were partially rescued, and showed a five-fold 
increase in cell number over control cultures maintained in FGF2-containing, insulin-free 
conditions and approximately half that of FGF2 and insulin-treated cultures (46.7 ± 
7.31% vs. 9.88 ± 2.30% vs. 100 ± 14.1%, p < 0.001, Fig. 3A). Similarly, in primary 
E13.5 cortical cultures, no difference was observed between nestin+ cell number 
maintained in FGF2 and PDGF-AA minus insulin and control, FGF2 and insulin-
containing cultures (100 ± 35.3% in FGF2+insulin vs. 58.1 ± 22.2% in FGF2+PDGF-AA 




To examine survival, FGF2-treated CNS stem cells were treated with or without insulin, 
and either co-stimulated with or switched from FGF2 to PDGF-AA for 3d. While fresh 
FGF2 and PDGF-AA were added daily, media was not changed from plating so that dead 
or dying cells in suspension would not be excluded from viability analyses. At 3 d, media 
supernatant containing viable and nonviable cells in suspension was combined with the 
HBSS-passaged, adherent progenitors. The cell suspensions were incubated with 
propidium iodide and analyzed by FACS sorting. Insulin withdrawal severely 
compromised the survival of FGF2-treated cells, resulting in a drop in viability (from 
61.88 ± 7.13% to 7.13 ± 4.94%, p < 0.001, Fig 3C). Addition of PDGF-AA (in the 
presence of FGF2) effectively prevented insulin withdrawal-induced reduction in 
viability, and even PDGF-AA alone (without FGF2 and insulin) showed high viability 
(FGF2+PDGF-AA minus insulin, and PDGF-AA minus FGF2 and insulin: 60.2 ± 6.02%, 
and 38.0 ± 6.01%, respectively; Fig 3C). 
 
We then analyzed the insulin masking effect on BrdU incorporation after a 3hr pulse. 
Similar to the effect on viability, insulin withdrawal, in the presence of FGF2, caused a 
marked reduction in BrdU incorporation (31.6 ± 1.00% in insulin vs. 10.2 ± 0.623% 
without insulin, p < 0.00001, Fig 3D). Co-stimulation with PDGF-AA and FGF2 or 
switching to PDGF-AA in FGF2 and insulin-free conditions largely abrogated the 
decrease in proliferation (FGF2+PDGF-AA minus insulin and PDGF-AA minus FGF2 
and insulin: 37.8 ± 1.09% and 26.6 ± 1.31%, respectively; Fig. 3D). In fact, even in the 
absence of insulin, PDGF-AA addition actually increased the proportion of cells 




Consistent with these results, the levels of p-mTOR, p-Akt, and p-Erk1/2 pathways 24 h 
following insulin withdrawal significantly decreased (Fig 3A). When cultures were co-
stimulated with PDGF-AA or switched to PDGF-AA alone following insulin withdrawal, 
increased activation of these pathways was evident.  
 
PDGF-AA promotes glucose metabolism 
 
Insulin is a well known factor that stimulates glucose metabolism through several 
pathways, including through PI3K/Akt activation (50, 51) .  Our results indicate that 
PDGF-AA is able to maintain an elevated level of phospho-Akt and high viability and 
proliferation without insulin, an effect strikingly distinct from FGF2. Therefore, to assess 
whether PDGF-AA alters glucose metabolism in CNS stem cells, we measured glycolytic 
rate in the presence and absence of insulin and PDGF-AA. As predicted, 24h after insulin 
withdrawal, glycolytic rate largely dropped (100 ± 21.4% vs. 29.3 ± 10.1%; p < 0.0001, 
Fig 3E). Co-stimulation with PDGF-AA, however, abrogated the decrease in glycolytic 
rate (FGF2+insulin: 100 ± 21.4% vs. FGF2+PDGF-AA minus insulin 80.9 ± 20.3%; p = 
0.105, Fig 3E). Switching to PDGF-AA alone showed much higher glycolytic rate than 
culture in FGF2 alone (56.3 ± 8.81%; p < 0.01, Fig 3E). Forty-eight hours after insulin 
withdrawal, the same pattern remained, and there was little difference in relative 




We next employed pharmacology to determine which pathways were required for the 
PDGF-mediated increase in glycolytic rate. Pretreatment with PD98059 and rapamycin 
nearly halved the glycolytic rate, while pretreatment with LY294002 reduced glycolytic 
rate to a level below cultures treated with FGF2 minus insulin (FGF2+PDGF-AA minus 
insulin: 80.9 ± 20.3%; FGF2+PDGF-AA+rapamycin minus insulin 44.4  ± 3.25%;  
FGF2+PDGF-AA+PD98059 minus insulin 42.2  ± 10.8%; FGF2+PDGF-AA+LY294002 
minus insulin 11.2 ± 3.25%. FGF2+PDGF-AA minus insulin vs. each inhibitor-treated 
group, p < 0.015, Fig 3E).  These data demonstrate that PI3K/Akt, MEK/Erk, and mTOR 
pathways mediate the PDGF-induced increase in glycolytic rate, and that PI3K/Akt is a 




Figure 3. PDGF-AA rescues nestin+ cell number, viability, and proliferation in the absence of 
FGF2 and insulin and increases glycolytic rate. (A) CNS stem cells were plated at low density and 
grown for 4 d ± FGF2 (F), PDGF-AA (P), and insulin (Ins). Cell number (mean ± s.d., n = 4, *p < 
0.001) is expressed as percent of control (FGF2). (B) Freshly dissected E13.5 primary cortical cells 
were plated at low density and grown for 4 d ± FGF2, PDGF-AA, and insulin (mean ± s.e.m., n.s. = 
non-significant [p = 0.09], *p < 0.02). (C) CNS stem cells were grown for 3 d ± FGF2, PDGF-AA, 
and insulin; viability was analyzed based on propidium-iodide exclusion using FACS (mean ± s.d., n 
= 3, *p < 0.003). (D) CNS stem cells were pulsed with BrdU for 3 h, fixed and then labeled with an 
anti-BrdU antibody (mean ± s.d., n = 3, *p < 0.003). (E) CNS stem cells were cultured for 24 or 48 h 
± F, P, Ins, LY, PD, or RAPA and glycolytic rate was measured. Glycolytic rate (mean ± s.d., n = 4, 
*p < 0.015) is expressed as percent of control (F+Ins). 
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PDGF-AA promotes oligodendrogliogenesis from CNS stem cells  
 
PDGF-AA treatment of CNS stem cells resulted in a rapid morphological change: by 24h, 
the majority of cells became phase-bright, and extended long bipolar processes. However, 
in the presence of PDGF-AA, all cells expressed neural progenitor markers including 
nestin and Sox2, and remained in the cell cycle, with virtually all cells undergoing S-
phase in 24h (Figs 1D-G, 2B). We found that, in order to induce exit from the cell-cycle 
and terminal differentiation, PDGF-AA had to be withdrawn from the culture medium. 
Given the morphological change and rapid activation of the PI3K/Akt and MEK/Erk 
pathways and their known involvement in CNS cell differentiation, we wondered if a 
transient exposure to PDGF-AA would be sufficient to alter differentiation. First-passage 
CNS stem cells were exposed to PDGF-AA for 12 h, and were switched to differentiation 
medium (Neurobasal + B27 supplement without PDGF-AA or FGF2) for 4-5 d. By 3-4 d, 
PDGF-AA treated cultures showed obvious oligodendroglial differentiation, with the 
majority of cells extending numerous fine processes. At 4-5d, PDGF-AA treated cultures 
were visibly enriched for oligodendrocytes. Immunocytochemistry with the 
oligodendrocyte-specific antibody, O4, confirmed that PDGF-AA treatment, either by co-
stimulation with FGF2 or switching to PDGF-AA alone, increased the proportion of 
oligodendrocytes by 2.3 and 2.8 fold, respectively (FGF2-only control: 21.4 ± 2.81%; 
FGF2+PDGF-AA:  49.3 ± 4.25%; FGF2 Æ PDGF-AA: 60.3 ± 0.918%. Control vs. each 
PDGF-AA treated group, p < 0.00003). These data demonstrate that transient exposure of 
CNS stem cells to PDGF-AA, for a duration roughly less than the length of a cell-cycle, 




An interesting feature of PDGF-AA treatment of CNS stem cells was that a short 
exposure to the cytokine had a robust, long-term effect on oligodendroglial differentiation. 
This feature allowed us to use pharmacologic inhibitors for a short period of time and 
minimize toxicity to cells, especially during the 4-5 d period of differentiation. To assess 
which PDGF-AA activated pathways, if any, were required to induce 
oligodendrogliogenesis from CNS stem cells, we pretreated CNS stem cells with 
LY294002 and PD98059 for 1h, and then added PDGF-AA in the presence of inhibitor 
for 12 h. After 12-13 h, the inhibitor and exogenous PDGF-AA (and FGF2) were washed 
out by replacing media with differentiation media. The PI3K/Akt and MEK/Erk pathways 
were specifically chosen because they are rapidly activated by PDGF-AA by 5 min and 
the elevated activity persists for 12h. Transient blockade of the PI3K/Akt pathway 
partially inhibited PDGF-AA mediated oligodendrogliogenesis, while the pro-
oligodendroglial effect of PDGF-AA was completely inhibited with blockade of the 
MEK/Erk pathway (FGF2+PDGF-AA+LY294002: 38.5 ± 4.71% [vs. FGF2 only, p < 
0.002; vs. FGF2+PDGF-AA, p < 0.025]; FGF2+PDGF-AA+PD98059: 26.0 ± 5.38% [vs. 
FGF2 only, p = 0.200; vs. FGF2+PDGF-AA, p < 0.0015]). Thus, while both the 
PI3K/Akt and MEK/Erk pathways are required for PDGF-AA mediated 




Figure 4. PDGF-AA promotes oligodendrogliogenesis from CNS stem cells. (A) CNS stem cells 
were plated at 25,000 cells/cm2 and pulsed for 12 h ± FGF2, PDGF-AA, LY, and/or PD (cultures were 
pretreated with inhibitors for 1h prior to PDGF-AA pulse). Cells in “PDGF-AA only” group were 
obtained by plating primary E13.5 cortical cells in PDGF-AA alone (no exogenous FGF2 was added) 
for 5-7 d, passaging, and plating at same density in (A). This enriched population of oligodendrocyte 
progenitors was treated with PDGF-AA for an additional 12 h. After cytokine and/or inhibitor 
treatment, cells were then switched to serum-free differentiation medium, cultured for 4-5 d, fixed, 
and labeled with anti-O4 antibody. Scale bar = 20 μm. (B) Percentage of O4+ oligodendrocytes of 
total cells (mean ± s.d., n = 4 [n = 3 for inhibitor-treated groups], *p < 0.025). 
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Transient exposure to PDGF-AA is associated with a delay in cell cycle exit during 
differentiation 
 
When CNS stem cells were exposed to PDGF-AA for only 12 h immediately prior to 
differentiation, it was clear, 4 d later, that this short pulse affected not only 
oligodendrogliogenesis, but also total cell number. In fact, differentiated cultures co-
stimulated with a 12 h pulse of PDGF-AA 4 d earlier had an approximate 2-fold increase 
in total cell number, but cell numbers in cultures switched from FGF2 to PDGF-AA, 
were not significantly different from FGF2-only control cultures (FGF2-only control: 499 
± 92.4 cells/field, FGF2+PDGF-AA: 956 ± 92.3, p < 0.005; FGF2ÆPDGF-AA: 732 ± 
143, p = 0.0826; Fig 5A). To account for the difference in cell number, we tracked 
proliferation and apoptosis rates. To monitor proliferation during differentiation, we 
pulsed parallel cultures with BrdU 2 h before fixation, every day for 4 d, and stained with 
a monoclonal anti-BrdU antibody to score cells undergoing S-phase. We assayed 
apoptosis, each day of differentiation, with a polyclonal antibody against caspase-3. 
Analysis of these parameters revealed that the differences in cell number were 
predominately due to delayed exit from the cell cycle among cells transiently exposed to 
PDGF-AA. In fact, 24h to 48h after withdrawal of PDGF-AA, treated cells exhibited a 
2.23 to 3.55-fold increase in BrdU incorporation versus control cultures (e.g. at 24 h, 
FGF2-only control: 11.8 ± 3.87%, FGF2+PDGF-AA: 42.1 ± 3.60%, p < 0.00075; 
FGF2ÆPDGF-AA: 26.5 ± 2.98%, p < 0.0075). By day 4 of differentiation, however, 




Figure 5. Transient exposure to PDGF-AA is associated with a delay in cell cycle exit during 
differentiation. (A) CNS stem cells were treated as in Fig 4A. Twelve, 36, 60, 84, and 108 hours after 
growth factor pulse, differentiating cells were fixed (BrdU was added 2 h before fixation as indicated), 
and cell number, (B) S-phase, and (C) apoptosis was measured by labeling with DAPI, anti-BrdU, and 




PDGF-AA enables direct derivation of oligodendrocyte progenitors from the 
embryonic cortex 
 
We found that primary cells from E12.5 – E15.5 lateral cortex directly with PDGF-AA 
alone (no FGF2 or insulin) were selected for embryonic lineage oligodendrocyte 
progenitors. Two to three days after PDGF-AA treatment of primary embryonic cortical 
cells, small foci of bipolar, phase-bright cells were visible. By 5-7d of treatment, these 
bipolar cells were 70-80% confluent, requiring passage. In the presence of PDGF-AA, 
these cells continued to divide, and could be passaged up to 4-5 times without FGF2 and 
insulin. Withdrawal of PDGF-AA induced oligodendroglial differentiation (addition of 
insulin is required for survival of differentiating cells): as high as 77.4 ± 4.67% were O4+ 





Clonal analysis shows that multipotent cells can be isolated from the CNS that give rise 
to neurons and glia (15). The proportion of differentiated cells can be regulated by single 
factors and the differentiation to astrocytes by activation of the Jak/STAT pathway has 
been widely studied as a model of fate choice (52-56).  A simple method to generate 
oligodendrocytes from CNS stem cells might also contribute to our understanding 
differentiation pathways.  Here we show that PDGF-AA, through PDGFRα, leads to a 
rapid increase in the proportion of oligodendrocyte progenitors. The growth factor 
stimulates rapid and long-lasting activation of Akt and Erk1/2 (57) but phosphorylation 
of Tyr705 on STAT3 was not observed (data not shown).  The use of pharmacological 
inhibitors suggests that the Erk pathway is required for differentiation but there may also 
be a role for Akt activation in oligodendrocyte differentiation. The generation of large 
numbers of oligodendrocyte progenitors by a brief treatment with PDGF-AA can now be 
used to analyze the molecular mechanisms controlling the specification of this fate.    
 
The PI3K/Akt pathway is a central mediator of glucose metabolism (50, 58, 59). 
Furthermore, glycolytic rate is highly correlated to cell viability and proliferation (24). 
Given that PDGF-AA treatment induced sustained Akt phosphorylation, increased 
survival and proliferation, especially in insulin-free culture, we investigated whether 
PDGF regulates glucose metabolism in CNS stem cells. PDGF-AA was as effective as 
insulin in increasing glycolytic rate and over 2.75-fold as effective as FGF2. Along with 
PI3K/Akt, we looked for other signaling mediators necessary for PDGF-AA regulation of 
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glycolytic rate. The rapamycin-sensitive, mTOR complex 1, is downstream of Akt and 
mediates several nutrient transport and metabolic functions (60).  Akt can activate mTOR, 
either by direct phosphorylation, or indirectly through inactivation of tuberin, and an 
activated mTOR mutant has been shown to maintain glycolytic rate in hematopoietic 
cells even in the absence of growth factor/Akt signaling (25). We found that rapamycin 
partially blocked the PDGF-AA increase of glycolytic rate. Additionally, we show that 
the MEK/Erk pathway is required for the PDGF-AA mediated increase in glycolytic rate 
in CNS stem cells. Indeed, MEK/Erk pathway has been shown to promote glycolysis in 
the setting of hypoxia and serum exposure by increasing expression of specific glycolytic 
enzymes (61, 62). 
 
We have shown that PDGFRα is expressed by virtually all CNS stem cells in vitro, and 
its specific ligand, PDGF-AA, can induce robust oligodendrogliogenesis (2.5-3 fold over 
control cultures; 50-60% of total cells) via a single 12 h pulse in serum-free culture 
conditions. The short nature of the cytokine exposure permitted us to interrogate 
intracellular signaling through the use of several pharmacologic inhibitors and had the 
added advantage of minimizing exposure to these inhibitors during the subsequent 4-5d 
differentiation period. While inhibition of PI3K/Akt pathway only partially blocked the 
pro-oligodendrogliogenic action of PDGF-AA, MEK/Erk blockade almost completely 
blocked this effect, when compared to control cultures. Thus the MEK/Erk pathway 
appears particularly important for PDGF-AA mediated oligodendrogliogenesis from CNS 




We have previously reported that continuous PDGF-AA treatment of rat embryonic and 
adult CNS stem cells promotes continued proliferation of a neuronal-type precursor, 
based on expression of the antigen, MAP2 (15).  However, there are also reports of 
MAP2 expression in the oligodendrocyte lineage (63, 64).  Also, given the potent 
mitogenic effect of PDGF-AA as observed by rapidly increasing cell number and BrdU 
incorporation, continued expression of nestin and Sox2, immature morphology, we 
wondered if withdrawal of the growth factor was required to allow cell cycle exit and 
terminal differentiation.  After withdrawal of FGF2 and PDGF-AA but in continued 
presence of N2 medium, we observed some degree of differentiation but this was 
accompanied by compromised viability and incomplete maturation. We used another 
chemically defined, widely used serum-free medium, Neurobasal plus B-27 supplement, 
to promote survival and differentiation of the cells. In this medium, a dramatic increase in 
survival and maturation of differentiating cells was observed. By 3-5 d, it was obvious 
that extensive oligodendroglial differentiation was taking place. Others have reported that 
short pulses of PDGF-AA enhances neuronal differentiation (65, 66), however these 
groups used non-purified, E12-E14 primary cortical progenitors, without prior expansion 
with FGF2; many of these primary cells are committed neuronal progenitors. In contrast, 
FGF2-expanded embryonic neural cells are relatively homogenous and highly enriched 
for multipotent stem cells (15), and thus were used as our starting population for signal 
transduction and differentiation assays. 
 
The enhanced proliferation of PDGF-AA treated cells may imply that the cytokine exerts, 
in part, a selective effect to promote oligodendrogliogenesis. However it remains possible 
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that the brief pulse of PDGF-AA may exert an instructive change in fate, and that, after 
PDGF-AA withdrawal, newly specified oligodendrocyte progenitors undergo a higher 
number of divisions than do neuronal and astrocyte-committed progenitors as they exit 
the cell cycle and differentiate. Furthermore, a potential instructive component in the 
action of PDGF-AA on CNS stem cells remains difficult to rule out as virtually all cells 
express PDGFRα, the cytokine pulse is brief, and that, in response to PDGF-AA, several 
signaling pathways are rapidly activated and most cells undergo extensive morphologic 
changes in less than 24 h. Therefore, there is evidence for both selective and instructive 
components in the action PDGF-AA to promote oligodendrogliogenesis from CNS stem 
cells. 
 
Our ability to generate mitotic oligodendrocyte progenitors from CNS stem cells and 
directly from mid- to late-gestation primary cortical cells, in serum-free conditions, may 
be particularly advantageous for cell transplantation, as well as for in vitro differentiation 
studies. While others have reported derivation of enriched oligodendrocyte progenitors 
from neonatal rodent neural stem cells, termed “oligospheres,” the method involves a 
lengthy selection procedure, including phased administration of B104 neuroblastoma 
conditioned medium over a period of days to weeks (67, 68). Similarly, the isolation of 
highly purified oligodendrocyte progenitors from the neonatal and postnatal CNS—well 
known for 25 years—requires extensive, multistep selection protocols (3, 69). In contrast, 
we describe a rapid, serum-free method, based on exposure to a single factor, to derive 
oligodendrocyte progenitors directly from CNS stem cells or embryonic cortex without 
inducing terminal differentiation. These oligodendrocyte progenitors continue to divide, 
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do not terminally differentiate, can be passaged 4-5 times in the absence of exogenous 
FGF2 and insulin, enabling the generation of tens of million progenitor cells from a 
single embryo (approximately one million oligodendrocyte progenitors can be generated 
from a single E13.5 embryo at first passage, after 5-7 d in vitro) cells). When PDGF-AA 
is withdrawn, cells differentiate into approximately 60-80% O4+ oligodendrocytes.  
 
Taken together, our study links particular signaling pathways downstream of PDGFRα to 
CNS stem cell growth, survival, metabolism, and fate. With the recent evidence for 
elimination for embryonic-lineage oligodendrocyte progenitors (2),  it will be interesting 
to compare fetal oligodendrocyte progenitors with those that are derived postnatally, as 
well as embryonic CNS stem cell-derived oligodendrocyte progenitors with those isolated 
directly from the embryonic cortex. If human oligodendrocyte progenitors can similarly 
be generated, this method presented here may be used to derive large numbers of these 
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